EUVIMEDEUVIMED entdecken
Kommentar

Ketamine dose reporting and dose responsiveness for chronic pain

Steven P Cohen iD, Chachrit Khunsriraksakul, Seffrah J Cohen, Jee Youn Moon iD

Pain Medicine · 2023

DOI: 10.1093/pm/pnad059 ↗

Kurz gefasst

Kommentar in der Zeitschrift Pain Medicine, 2023. Verfasst von Steven P Cohen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Anesthesiology & Critical Care Medicine, Neurology, Physical Medicine & Rehabilitation, and Psychiatry & Behavioral Sciences, Johns Ho…. Hauptthemen laut MEDLINE: Ketamine, Chronic Pain. Die Arbeit nennt 8 Literaturangaben. Gefördert von: MIRROR, Uniformed Services University of the Health Sciences, Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dear Editor, On behalf of our authors, we thank Dr. Andrassy and colleagues for their thoughtful letter in response to our recent article.1 As randomized and nonrandomized studies have generally found a dose-response relationship for chronic pain,2 we appreciate their pointing out the oversight with regard to stratifying outcomes by ketamine dose. In our study, the mean dose of ketamine in treatment responders was 209.66 ± 160.68 mg, vs 144.04 ± 133.68 mg in those with a negative outcome (P = .068). There was, however, a moderate correlation between pain reduction after ketamine infusion at 4-week or longer follow-up and ketamine dose (R = 0.42; P = .001; Figure 1). Scatter plot demonstrating a moderate correlation between ketamine dose and pain reduction at ≥4-week follow-up. The “methodology” used to calculate ketamine dosing was chart review. Although the basis for dosing cannot be gleaned from the medical records, it was probably related to numerous factors, including age, weight, provider preference, and institutional policies. At Walter Reed and Johns Hopkins, we typically try to provide as high a dose as tolerated in as short a time period as possible, as one review found that in 37.5% of studies the antidepressant effect correlated with psychomimetic effects, and higher doses and more rapid administration typically cause more psychomimetic effects.3 Because ketamine dose correlates with psychomimetic effects for mood disorders4 and alleviating the affective–motivational component of pain could account for prolonged benefit as we hypothesized, this makes intuitive sense. With regard to our use of milligrams rather than milligrams per kilogram to denote dosing, we agree that adding the latter would have provided additional insight, but the contemporaneous weight of all subjects was not available. Moreover, randomized trials evaluating ketamine for chronic pain have generally been mixed with regard to reporting the dose in total milligrams vs milligrams per kilogram,2,5,6 and the only formulation of ketamine approved for a chronic condition in the United States, Spravato (Janssen Pharmaceuticals, Titusville, NJ, USA), is dosed in 28-mg increments rather than on a milligrams-per-kilogram basis.7 In contrast, for acute pain (including the US Food and Drug Administration guidelines for anesthetic induction), dosing information in the form of milligrams per kilogram tends to be much more common. It should be noted that complex regional pain syndrome is by definition a chronic condition, so referencing the chronic pain guidelines rather than the acute pain guidelines would have been more relevant. In the chronic pain guidelines and in a highly publicized meta-analysis evaluating randomized trials of ketamine for chronic pain, the recommended dosages are provided in milligrams rather than in milligrams per kilogram.2,8 In conclusion, we are grateful for the insightful comments by Dr. Andrassy and colleagues and appreciate the opportunity to provide the important information they requested, as well as to clarify any misconceptions. Funded by MIRROR, Uniformed Services University of the Health Sciences, US Department of Defense, Grant # HU00011920011. Conflicts of interest: None declared.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineChronic PainHumansAnesthetics, DissociativeAnalgesics

Substanzen

KetamineAnesthetics, DissociativeAnalgesics

Autor:innen und Institutionen

  • Departments of Anesthesiology & Critical Care Medicine, Neurology, Physical Medicine & Rehabilitation, and Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
  • Departments of Physical Medicine & Rehabilitation and Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States.
  • Medical Student, Penn State College of Medicine, Hershey, PA 17033, United States.
  • River Hill High School, Clarksville, MD 21029, United States.
  • Department of Anesthesiology, Seoul National University College of Medicine, Seoul 03080, Korea.

ORCID-Profile: Steven P Cohen, Jee Youn Moon

Förderung

  • MIRROR
  • Uniformed Services University of the Health Sciences
  • Department of Defense

Zitieren

APA

Cohen, S. P., Khunsriraksakul, C., Cohen, S. J., & Moon, J. Y. (2023). Ketamine dose reporting and dose responsiveness for chronic pain. Pain Medicine. https://doi.org/10.1093/pm/pnad059

Vancouver

Cohen SP, Khunsriraksakul C, Cohen SJ, Moon JY. Ketamine dose reporting and dose responsiveness for chronic pain. Pain Medicine. 2023. doi:10.1093/pm/pnad059

BibTeX
@article{Cohen2023,
  author = {Cohen, Steven P and Khunsriraksakul, Chachrit and Cohen, Seffrah J and Moon, Jee Youn},
  title = {Ketamine dose reporting and dose responsiveness for chronic pain},
  journal = {Pain Medicine},
  year = {2023},
  doi = {10.1093/pm/pnad059}
}
Kostenlos starten →